Altamira Therapeutics Faces Nasdaq Delisting Risk

TL;DR

Nasdaq says Altamira's stock is too cheap, needs to fix it by March 2025 or get booted.

AI Summary

Altamira Therapeutics Ltd. received a letter on September 30, 2024, from the Nasdaq Listing Qualifications department regarding its non-compliance with the minimum bid price requirement. The company was previously notified on July 1, 2024, that its American Depositary Shares (ADSs) had a closing bid price of less than $1.00 for 30 consecutive business days. Altamira has until March 30, 2025, to regain compliance.

Why It Matters

Failure to meet Nasdaq's minimum bid price requirement could lead to the delisting of Altamira's ADSs, potentially impacting liquidity and investor confidence.

Risk Assessment

Risk Level: medium — The company is at risk of delisting from Nasdaq if it cannot meet the minimum bid price requirement within the specified timeframe.

Key Numbers

• $1.00 — Minimum Bid Price (The minimum closing bid price required by Nasdaq for continued listing.)
• March 30, 2025 — Compliance Deadline (The date by which Altamira Therapeutics must meet Nasdaq's minimum bid price requirement.)

Key Players & Entities

• Altamira Therapeutics Ltd. (company) — The company filing the report and subject to Nasdaq listing rules.
• Nasdaq Listing Qualifications (company) — The department that issued the non-compliance letter.
• September 30, 2024 (date) — Date the company received the non-compliance letter.
• July 1, 2024 (date) — Date of the initial notification of non-compliance.
• March 30, 2025 (date) — Deadline for Altamira Therapeutics to regain compliance with Nasdaq listing rules.
• $1.00 (dollar_amount) — The minimum bid price requirement for Nasdaq listing.

FAQ

Key Financial Figures

• $1.00 — ties to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price

Filing Documents

• ea0216654-6k_altamira.htm (6-K) — 16KB
• ea021665401ex99-1_altamira.htm (EX-99.1) — 6KB
• 0001213900-24-085537.txt ( ) — 24KB

Forward-Looking Statements

Forward-Looking Statements This Report on Form 6-K contains “forward-looking by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this Report on Form 6-K include, without limitation, statements regarding the Company’s intent or ability to regain compliance with the Minimum Bid Price Requirement, the outcome of the Nasdaq hearing and appeal process, and the anticipated actions by the Nasdaq staff and the Company’s responses and their anticipated outcome, and the ability for the common shares to remain listed on Nasda q. Any forward-looking statements in this Report on Form 6-K are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. 1 INCORPORATION BY REFERENCE This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Numbers 333-249347 , 333-261127 , 333-264298 , 333-267584 , 333-272338 , and 333-276427 ) and Form S-8 (Registration Numbers 333-232735 , 333-252141 , and 333-278595 ) of Altamira Therapeutics Ltd. (formerly Auris Medical Holding Ltd.) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Number Description 99.1 Press release, dat

View Full Filing

View this 6-K filing on SEC EDGAR